Cancer and COVID-19 vaccines: a complex global picture - 02/06/21

Doi : 10.1016/S1470-2045(21)00244-8

Aasim Yusuf ^a, Diana Sarfati ^b, Christopher M Booth ^c, C S Pramesh ^d, Dorothy Lombe ^e, Ajay Aggarwal ^f,^o, Nirmala Bhoo-Pathy ^g, Audrey Tsunoda ^h, Verna Vanderpuye ⁱ, Tezer Kutluk ^j, Alice Sullivan ^k, Deborah Mukherji ^l, Miriam Mutebi ^m, Mieke van Hemelrijck ⁿ, Richard Sullivan ^o
on behalf of the
COVID-19 and Cancer Global Taskforce

^a Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan

^b National Director of Cancer Control, and Chief Executive Cancer Control Agency, Wellington, New Zealand

^c Queen’s University Cancer Research Institute, Kingston, ON, Canada

^d Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India

^e Cancer Diseases Hospital, Lusaka, Zambia

^f London School of Hygiene & Tropical Medicine, London, UK

^g Faculty of Medicine, University Malaya, Malaysia

^h Hospital Erasto Gaertner, PPGTS/Pontifícia Universidade Católica do Paraná, Curitiba, Brazil

ⁱ National Center for Radiotherapy, Oncology and Nuclear Medicine, Korlebu Teaching Hospital, Accra, Ghana

^j Department of Pediatric Oncology, Hacettepe University Faculty of Medicine & Cancer Institute, Sıhhiye-Ankara, Turkey

^k School of Life Sciences, University of Warwick, Coventry, UK

^l Faculty of Medicine, American University of Beirut, Beirut, Lebanon

^m Breast Surgical Oncology, Aga Khan University, Nairobi, Kenya

ⁿ Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK

^o Institute of Cancer Policy, School of Cancer & Pharmaceutical Sciences, King’s College London & Guy’s and St Thomas’ NHS Trust, London, UK

El texto completo de este artículo está disponible en PDF.